It's never bad news to have your results published in more articles, but I don't understand why PIQ need to keep demonstrating this. The business is marketing PromarkerD as "shelf ready" (and has been for years now, correct me if I am wrong), so why the need to keep validating I don't understand - can someone explain?
I would have thought at this point in time the announcements should be business deals related, not further validation? I'm just confused, the path to commercialisation is so cloudy for me....
Ann: PromarkerD clinical assay performance results published, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
-0.015(4.41%) |
Mkt cap ! $53.14M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $72.42K | 217.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9795 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 53089 | 4 |
View Market Depth
| Last trade - 14.27pm 24/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |